REFERENCES
- Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. Ann Intern Med. 2003; 139: 313–320, 2003;
- Gallant JE, Staszeweski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naïve patients: A three-year randomized trial. JAMA. 2004; 292: 191–201, 2004;
- Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006; 354: 251–260
- Perazella MA. Drug-induced renal failure: Update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci. 2003; 325(6)349–362
- Imoka A, Kusuhara H, Adachi M, et al. Functional involvement of multidrug-resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007; 71: 619–627, 2007;
- Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi Syndrome, and nephrogenic diabetes insipdus. Clin Infect Dis. 2003; 36: 1070–1073
- Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005; 40: 1194–1198
- Coca S, Perazella MA. Acute renal failure associated with tenofovir: Evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002; 324(6)342–344
- Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003; 37: 944–950
- Ray SA, Cihlar T, Robinson KL, et al. Mechanism of acute renal tubular efflux of tenofovir. Anitmicrob. Agents Chemother. 2006; 50(10)3297–3304
- Ray AS, Cihlar T. Unlikely association of multidrug-resistance protein-2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events. CID. 2007; 195: 1389
- Louie SG, Lam JT, Neely MN, Beringer P. Multidrug resistance protein-2 (MRP-2) inhibition by ritonavir (RTV) increases tenofovir (TDF)-associated cytotoxicity. Poster 2.16. Program and abstracts of the Sixth International Workshop on Clinical Pharmacology of HIV Therapy. QuebecCanada 2005
- Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. JID. 2006; 194: 1481–1491
- Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently. J Acquir Immune Defic Syndr. 2004; 37: 1489–1495